Figure 3.
EFS and OS in patients with high BCL2/MYC coexpression by treatment arm and age. EFS and OS in patients with high BCL2/MYC coexpression by RNA-seq in the placebo plus R-CHOP and ibrutinib plus R-CHOP arms, aged <60 years (A,B) and ≥60 years (C,D).

EFS and OS in patients with high BCL2/MYC coexpression by treatment arm and age. EFS and OS in patients with high BCL2/MYC coexpression by RNA-seq in the placebo plus R-CHOP and ibrutinib plus R-CHOP arms, aged <60 years (A,B) and ≥60 years (C,D).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal